Vanadis Core® qualitative assay for screening the risk of trisomy 21, 18, and/or 13.
Qualitative assay intended for an in vitro diagnostic use to act as an aid in screening for the risk of trisomy 21, 18, and/or 13 in fetus using cell-free DNA from pregnant women of at least 10 weeks of gestation.
Application |
Noninvasive Prenatal Testing (NIPT)
|
---|---|
Brand |
Vanadis Core®
|
Product Compatibility |
Vanadis Core®
|
We are here to answer your questions.